cerrar
Tagged with US

Novavax: From No-Hoper to COVID-19 Vaccine Saviour?
From almost being de-listed by the NASDAQ stock index in 2018 due to poor financial performance, US vaccine firm Novavax has completed a remarkable…

The COVID-19 Vaccine Rush: Nationalism, Access & IP Issues
The global rush to secure access to COVID-19 vaccines has led to accusations that richer countries are hoarding supply at the expense of poorer…

Nawal Roy – Founder & CEO, Holmusk
Nawal Roy of global digital health platform Holmusk which aims to establish data as a core utility to the treatment of behavioural health disorders…

Italy: Stevanato’s $5 bn valuation; Zolgensma Approval; Sputnik…
The latest from Italian pharma, including the foreign minister’s plea for delivering on COVID-19 vaccine contracts, glass vial manufacturer…

Dan Leonard – President & CEO, Association for…
Dan Leonard, president and CEO of the Association for Accessible Medicines (AAM) since August 2020, outlines his key agenda priorities as head of the…

USA: 2 Things the Biden Administration can do Now to Lower Costs…
PhRMA’s Stephen J. Ubl outlines two ways in which the new US presidency can help lower healthcare costs and why biopharmaceutical companies support…

China: AstraZeneca/Junshi anti-PD-1 Tie-Up; New UK Biologics Plan…
The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and dMed’s R&D collab; and investment…

Mexico: US Vaccine Tourism; CanSino Stepping Up; AMLO Calls for…
The latest from Mexico’s fight against COVID-19, including news of vaccine tourism into the US, how China’s CanSino is filling the gaps left by…

NORD Chief Strategy Officer on Health Equity’s Vital…
With Rare Disease Day coming up on February 28th, one of the leading organizations dedicated to serving affected patients in the US, the National…

Securing the Conditions to Secure Our Meds
The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar medicines have on US healthcare today and introduces the ‘Secure…

IFPMA’s Thomas Cueni on why “#TeamVaccines is all of…
Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) highlights the incredible progress of COVID-19…

The bright future of mRNA technology – InConversation…
Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine,…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here